Ampio Pharmaceuticals, Inc. (AMPE) Completes Expanded Patient Enrollment for Study of Anti-inflammatory Candidate
Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities (NMEs), today announced it has completed the expanded patient enrollment phase of its Ampion™ In Knee (AIK) trials in Australia, adding 42 patients to the original 60-patient study. Ampion is the company’s non-steroidal anti-inflammatory drug that appears to have a significant role in the homeostasis of inflammation. Ampio believes this gives the drug the potential to be used in a broad array of inflammatory conditions. Ampio Chief Regulatory Officer Dr. Vaughan Clift noted the importance of the initial clinical trial, which…